Cargando…
Antiviral drugs against SARS-CoV-2
The use of antiviral drugs represents an important progress in the therapeutic management of COVID-19, leading to a substantial reduction of SARS-CoV-2-related complications and mortality. In immunocompetent host, peak viral replication occurs around the symptom’s onset, and it prolongs for 5 to 7 d...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Quimioterapia
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717461/ https://www.ncbi.nlm.nih.gov/pubmed/36285850 http://dx.doi.org/10.37201/req/s03.03.2022 |
_version_ | 1784842906857635840 |
---|---|
author | Aiello, Tommaso Francesco García-Vidal, Carolina Soriano, Alex |
author_facet | Aiello, Tommaso Francesco García-Vidal, Carolina Soriano, Alex |
author_sort | Aiello, Tommaso Francesco |
collection | PubMed |
description | The use of antiviral drugs represents an important progress in the therapeutic management of COVID-19, leading to a substantial reduction of SARS-CoV-2-related complications and mortality. In immunocompetent host, peak viral replication occurs around the symptom’s onset, and it prolongs for 5 to 7 days that is the window of opportunity for giving an antiviral. Accordingly, early and rapid diagnostic of the infection in the outpatient clinic is essential as well as the availability of oral agents that can be easily prescribe. Remdesivir has demonstrated its efficacy in hospitalized patients requiring oxygen support and in mild/moderate cases to avoid the hospitalization, however, the intravenous administration limits its use among outpatients. Molnupiravir and nirmatrelvir/ ritonavir are potent oral antiviral agents. In the present review we discuss the potential targets against SARS-CoV-2, and an overview of the main characteristics and clinical results with the available antiviral agents for the treatment of SARS-CoV-2. |
format | Online Article Text |
id | pubmed-9717461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Sociedad Española de Quimioterapia |
record_format | MEDLINE/PubMed |
spelling | pubmed-97174612022-12-08 Antiviral drugs against SARS-CoV-2 Aiello, Tommaso Francesco García-Vidal, Carolina Soriano, Alex Rev Esp Quimioter Approach to management of SARS-CoV-2 infection The use of antiviral drugs represents an important progress in the therapeutic management of COVID-19, leading to a substantial reduction of SARS-CoV-2-related complications and mortality. In immunocompetent host, peak viral replication occurs around the symptom’s onset, and it prolongs for 5 to 7 days that is the window of opportunity for giving an antiviral. Accordingly, early and rapid diagnostic of the infection in the outpatient clinic is essential as well as the availability of oral agents that can be easily prescribe. Remdesivir has demonstrated its efficacy in hospitalized patients requiring oxygen support and in mild/moderate cases to avoid the hospitalization, however, the intravenous administration limits its use among outpatients. Molnupiravir and nirmatrelvir/ ritonavir are potent oral antiviral agents. In the present review we discuss the potential targets against SARS-CoV-2, and an overview of the main characteristics and clinical results with the available antiviral agents for the treatment of SARS-CoV-2. Sociedad Española de Quimioterapia 2022-10-24 2022 /pmc/articles/PMC9717461/ /pubmed/36285850 http://dx.doi.org/10.37201/req/s03.03.2022 Text en © The Author 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). |
spellingShingle | Approach to management of SARS-CoV-2 infection Aiello, Tommaso Francesco García-Vidal, Carolina Soriano, Alex Antiviral drugs against SARS-CoV-2 |
title | Antiviral drugs against SARS-CoV-2 |
title_full | Antiviral drugs against SARS-CoV-2 |
title_fullStr | Antiviral drugs against SARS-CoV-2 |
title_full_unstemmed | Antiviral drugs against SARS-CoV-2 |
title_short | Antiviral drugs against SARS-CoV-2 |
title_sort | antiviral drugs against sars-cov-2 |
topic | Approach to management of SARS-CoV-2 infection |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717461/ https://www.ncbi.nlm.nih.gov/pubmed/36285850 http://dx.doi.org/10.37201/req/s03.03.2022 |
work_keys_str_mv | AT aiellotommasofrancesco antiviraldrugsagainstsarscov2 AT garciavidalcarolina antiviraldrugsagainstsarscov2 AT sorianoalex antiviraldrugsagainstsarscov2 |